A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 17 Feb 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs INCB 62079 (Primary)
Indications Biliary cancer; Cholangiocarcinoma; Liver cancer; Nasopharyngeal cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man; Proof of concept
Sponsors Incyte Corporation

14 Feb 2023 protocol amendment requiring pretreatment C4 concentrations < 40.9 ng/mL and concomitant prophylactic bile acid sequestrant treatment.
14 Feb 2023 Results(n=23) assessing safety and tolerability of INCB062079 in Patients with Advanced Solid Tumors published in the Targeted Oncology
13 Jul 2020 Status changed from recruiting to discontinued.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com